Shanghai Junshi Biosciences (HKG:1877, SHA:688180) received a Drug Registration Certificate for toripalimab after China's National Medical Products Administration approved a supplemental new drug application.
The approval comes for the use of the drug as the first-line treatment for unresectable or metastatic melanoma, an April 25 Hong Kong bourse filing said.
This marks the approval of toripalimab's 12th indication in the Chinese mainland.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.